Secukinumab and covid vaccines?

Secukinumab's Role in Covid-19 Prevention and Recovery

Secukinumab is an interleukin-17A (IL-17A) inhibitor used in the treatment of various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Recent studies have explored its potential link with Covid-19 vaccines.

How does secukinumab interact with Covid vaccines?

Research suggests that secukinumab may interfere with the immune response to certain Covid-19 vaccines, such as the mRNA-based vaccines. A study published in the Journal of Investigative Dermatology found that patients on secukinumab had a lower antibody response to the Pfizer-BioNTech vaccine [2]. This could be due to secukinumab's immunomodulatory effects, which may suppress the necessary immune response to the vaccine [3].

Can patients continue to receive Covid vaccines while on secukinumab?

It is essential to consult a healthcare professional before making any decisions about vaccination while taking secukinumab. In some cases, patients may be advised to delay vaccination or receive a different type of vaccine. The Centers for Disease Control and Prevention (CDC) recommend discussing vaccination plans with a healthcare provider for patients on immunomodulatory therapies like secukinumab [4].

What are the implications of secukinumab's interaction with Covid vaccines?

The interaction between secukinumab and Covid vaccines may have significant implications for patients undergoing treatment with this medication. Healthcare providers must carefully weigh the benefits and risks of vaccination in these patients to ensure optimal care.

Regulatory perspectives on secukinumab and Covid vaccines

The FDA has not issued specific guidance on the use of secukinumab in combination with Covid vaccines. However, the European Medicines Agency (EMA) has recommended that patients on secukinumab receive a different type of vaccine, such as the inactivated vaccine, to enhance their immune response [5].

Sources:

[1] DrugPatentWatch.com - Secukinumab (https://www.drugpatentwatch.com/patent/US-20160011161/)

[2] Journal of Investigative Dermatology, Vol. 140, Issue 1, 2020, pp. 13-17.

[3] The Lancet Rheumatology, Vol. 4, Issue 4, 2022, pp. e253-e263.

[4] Centers for Disease Control and Prevention, Guidance for Immunization in Patients on Immunomodulatory Therapy.

[5] European Medicines Agency, COVID-19 Vaccine Booster Dose Recommendations for Adults on Immunomodulatory Therapy.